15th May 2025 07:00
15 May 2025
LungLife AI, Inc. (the "Company" or "LungLife")
Block Admission Six Monthly Return
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block admission pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:
Name of Company: | LungLife AI, Inc. | |||
Name of scheme: | 1. 2010 Stock Incentive Plan 2. 2020 Stock Incentive Plan 3. 2021 Omnibus Long-Term Incentive Plan | |||
Number and class of securities originally admitted: | 1,356,139 common shares of US $0.0001 each | |||
Date of admission: | 15 November 2021 | |||
Period of return: | From: | 15 November 2024 | To: | 15 May 2025 |
Balance of unallotted securities under scheme(s) from previous return: | 1. 475,583 2. 201,374 3. 673,990 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 1. NIL 2. NIL 3. NIL | |||
Less: Number of securities issued/allotted under scheme(s) during period: | 1. NIL 2. NIL 3. NIL | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period : | 1. 475,583 2. 201,374 3. 673,990 | |||
Total number of securities in issue at the end of the period | 30,658,603 | |||
Name of contact: | David Anderson, Chief Financial Officer |
Telephone number of contact: | +44 (0)20 7933 8780 |
For further information please contact:
LungLife AI, Inc. | www.lunglifeai.com | |
Paul Pagano, CEO | ||
David Anderson, CFO |
| |
|
| |
Allenby Capital Limited Nominated Adviser and Joint Broker Alex Brearley / Lauren Wright - Corporate Finance Matt Butlin / Guy McDougall - Equity Sales & Corporate Broking | Tel: +44 (0)20 3328 5656
| |
|
| |
Goodbody (Joint Broker) | Tel: +44 (0) 20 3841 6202 | |
Tom Nicholson / Cameron Duncan |
| |
|
| |
About LungLife
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com.
Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.
Related Shares:
Lunglife Ai